Marshall Wace
TENX icon

Marshall Wace’s Tenax Therapeutics TENX Stock Holding History

Marshall Wace’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.64M Buy
352,572
+54,419
+18% +$736K 0.01% 1246
2025
Q4 		$3.63M Buy
298,153
+120,944
+68% +$1.05M ﹤0.01% 1299
2025
Q3 		$1.35M Buy
+177,209
New +$1.08M ﹤0.01% 1806

Other funds holding TENX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Marshall Wace's TENX Position: Q1 2026 in Review

Marshall Wace increased its Tenax Therapeutics (TENX) stake by 18% in Q1 2026, buying an estimated $736K and bringing the position to 352,572 shares worth $5.64M. The position accounts for 0.01% of the portfolio, ranked #1246.

Marshall Wace first reported a position in TENX in Q3 2025 and has held it in 3 quarters since. 80 funds tracked by Wall St. Rank hold TENX as of Q1 2026.

  • Marshall Wace held 352,572 shares of Tenax Therapeutics worth $5.64M as of Q1 2026.
  • Marshall Wace bought 54,419 Tenax Therapeutics shares in Q1 2026, an estimated $736K.
  • Tenax Therapeutics made up 0.01% of Marshall Wace's portfolio in Q1 2026, its #1246 holding.
  • Marshall Wace first reported a position in Tenax Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 80 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.